DOCSLIB.ORG

Heterogeneity and Evolution in Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Heterogeneity and Evolution in Cancer Madrid 23 — 25 Sept 2019 Heterogeneity and Evolution in Cancer Organisers Speakers Fátima Al-Shahrour Alexander R.A. Benjamin D. Guillermina Lozano Anderson Greenbaum Spanish National Cancer Research Centre, Univerity of Texas Anderson CNIO, Madrid, Spain Moffitt Cancer Center and Icahn School of Medicine at Cancer Centre, Houston, US Research Institute, Tampa, Mount Sinai, New York, US Arnold Levine US Marta Łuksza The Simons Center for Systems Biology, Holger Heyn Niko Beerenwinkel Icahn School of Medicine, Institute for Advanced Study, Princeton, US National Centre for Genomic Mount Sinai, New York, US ETH Zürich, Switzerland Analysis, Barcelona, Spain David Posada Solip Park Ivana Bozic Nancy Jenkins School of Biology, Spanish National Cancer Research Centre, University of Washington, US University of Texas MD University of Vigo, Spain CNIO, Madrid, Spain Anderson Cancer Center, Curtis G. Callan Houston, US Carol Prives Raúl Rabadán Princeton University, US Tal Korem Columbia University, Columbia Systems Biology, Columbia New York, US Neal G. Copeland Columbia University Irving University, New York, US University of Texas MD Medical Center, New York, US Benjamin J. Raphael Anderson Cancer Center, Christina Leslie Lewis-Sigler Institute for Houston, US Integrative Genomics, Memorial Sloan Kettering Princeton University, US Christina Curtis Cancer Center, New York, US Stanford University, School of Darryl Shibata Arnold Levine Medicine, Stanford, US Keck School of Medicine of The Simons Center for USC, Los Angeles, US Adolfo Ferrando Systems Biology, Institute for Institute for Cancer Genetics, Advanced Study, Princeton, US Andrea Sottoriva Columbia University Medical Nuria Lopez-Bigas The Institute of Cancer Center, New York, US Research, London, UK Institute for Research in Trevor Graham Biomedicine, Barcelona, Doug Winton Barts Cancer Institute, Spain Cancer Research UK London, UK Scott W. Lowe Cambridge Institute, Cambridge, UK Memorial Sloan Kettering Cancer Center, New York, US Madrid 23 — 25 Sept 2019 Heterogeneity and Evolution in Cancer 02 CNIO - LA CAIXA FRONTIERS MEETINGS | 2019 Madrid 23 — 25 Sept 2019 Heterogeneity and Evolution in Cancer # #CFM_CancerHeterogeneity @CNIO_Cancer @CaixaCiencia Madrid 23 — 25 Sept 2019 Heterogeneity and Evolution in Cancer 04 CNIO - LA CAIXA FRONTIERS MEETINGS | 2019 Madrid 23 — 25 Sept 2019 Heterogeneity and Evolution in Cancer Summary 07 ORGANISERS & SPEAKERS 11 PROGRAMME SESSIONS 19 S #1 Monday 09:45 - 12:45 27 S #2 Monday 14:15 - 16:45 35 S #3 Tuesday 09:00 -11:15 41 S #4 Tuesday 11:15 13:30 47 S #5 Tuesday 15:00 - 17:30 53 S #6 Wednesday 09:30 - 12:00 63 ORGANISERS & SPEAKERS’ BIOGRAPHIES 93 POSTER SESSION 117 Previous CNIO Frontiers Meetings and CNIO Cancer Conferences CNIO - LA CAIXA FRONTIERS MEETINGS | 2019 05 Madrid 23 — 25 Sept 2019 Heterogeneity and Evolution in Cancer 06 CNIO - LA CAIXA FRONTIERS MEETINGS | 2019 Madrid 23 — 25 Sept 2019 Heterogeneity and Evolution in Cancer Organisers and Speakers CNIO - LA CAIXA FRONTIERS MEETINGS | 2019 07 ORGANISERS AND SPEAKERS Madrid 23 — 25 Sept 2019 Heterogeneity and Evolution in Cancer Venue: Spanish National Cancer Research Centre – CNIO Auditorium, Madrid, Spain Chairpersons and organising committee: Fátima Al-Shahrour Arnold Levine Solip Park Raúl Rabadán Spanish National Cancer Research The Simons Center for Systems Spanish National Cancer Columbia Systems Biology, Centre, CNIO, Madrid, Spain Biology, Institute for Advanced Research Centre, CNIO, Columbia University, Study, Princeton, US Madrid, Spain New York, US Rationale: Cancers are dynamical and heterogeneous biological processes. Heterogeneity and evolution are the main factors driving oncogenesis, growth, invasion and failure of therapy. Longitudinal, multi-sampling and single cell genomic and transcriptomic characterization of tumors allows to reconstruct their changes and to link them to clinically relevant phenotypes. This workshop will bring together a community of interdisciplinary researchers HETEROGENEITY AND EVOLUTION IN CANCER HETEROGENEITY developing tools to study these processes and applying them to large numbers of tumors. 08 CNIO - LA CAIXA FRONTIERS MEETINGS | 2019 ORGANISERS AND SPEAKERS Speakers Alexander R.A. Benjamin D. Guillermina Lozano Anderson Greenbaum Univerity of Texas Anderson Moffitt Cancer Center and Icahn School of Medicine at Cancer Centre, Houston, US Research Institute, Tampa, Mount Sinai, New York, US US Marta Łuksza Holger Heyn Icahn School of Medicine, Niko Beerenwinkel National Centre for Genomic Mount Sinai, New York, US AND EVOLUTION IN CANCER HETEROGENEITY ETH Zürich, Switzerland Analysis, Barcelona, Spain David Posada Ivana Bozic Nancy Jenkins School of Biology, University of Washington, US University of Texas MD University of Vigo, Spain Anderson Cancer Center, Curtis G. Callan Houston, US Carol Prives Princeton University, US Tal Korem Columbia University, New York, US Neal G. Copeland Columbia University Irving University of Texas MD Medical Center, New York, US Benjamin J. Raphael Anderson Cancer Center, Christina Leslie Lewis-Sigler Institute for Houston, US Integrative Genomics, Memorial Sloan Kettering Princeton University, US Christina Curtis Cancer Center, New York, US Stanford University, School of Darryl Shibata Arnold Levine Medicine, Stanford, US Keck School of Medicine of The Simons Center for USC, Los Angeles, US Adolfo Ferrando Systems Biology, Institute for Institute for Cancer Genetics, Advanced Study, Princeton, US Andrea Sottoriva Columbia University Medical Nuria Lopez-Bigas The Institute of Cancer Center, New York, US Research, London, UK Institute for Research in Trevor Graham Biomedicine, Barcelona, Doug Winton Barts Cancer Institute, Spain Cancer Research UK London, UK Scott W. Lowe Cambridge Institute, Cambridge, UK Memorial Sloan Kettering Cancer Center, New York, US CNIO - LA CAIXA FRONTIERS MEETINGS | 2019 09 10 CNIO - LA CAIXA FRONTIERS MEETINGS | 2019 Madrid 23 — 25 Sept 2019 Heterogeneity and Evolution in Cancer Programme CNIO - LA CAIXA FRONTIERS MEETINGS | 2019 11 PROGRAMME 23rd September 2019 - Monday 09:00 Registration 09:30 - 09:45 Opening Remarks (Fátima Al-Shahrour and Raul Rabadan) 09:45 - 12:45 S#1 Chairperson: Raul Rabadan 09:45 - 10:15 “The roles of initiating truncal mutations in human cancers: the order of mutations and the tumor cell type matters” Arnold Levine The Simons Center for Systems Biology, Institute for Advanced Study, US 10:15 - 10:45 “Rapid evolution and biogeographic spread in a colorectal cancer” David Posada School of Biology, University of Vigo, Spain 10:45 - 11:15 Group picture (main door) & coffee break (social room) 11:15 - 11:45 “Single-Cell RNA sequencing: from sample to cell atlas” Holger Heyn National Centre for Genomic Analysis (CNAG-CRG), Barcelona, Spain 11:45 - 12:00 “Tracing the evolutionary history of clonal competition in mouse polymutated esophageal epithelium” HETEROGENEITY AND EVOLUTION IN CANCER HETEROGENEITY Gabriel Piedrafita Spanish National Cancer Research Centre, Madrid, Spain 12:00 - 12:15 “Genomic and immunological study of response to anti-PD-1 immunotherapy in glioblastoma” Andrew Chen Columbia University, New York, US 12 CNIO - LA CAIXA FRONTIERS MEETINGS | 2019 PROGRAMME 23rd September 2019 - Monday 12:15 - 12:45 “Learning tumor phylogenies from single-cell data” Niko Beerenwinkel ETH Zürich, Switzerland 12:45 - 14:15 Lunch break (cafeteria) 14:15 - 17:00 S#2 Chairperson: Arnold Levine 14:15 - 14:45 “Harnessing transposon mutagenesis to AND EVOLUTION IN CANCER HETEROGENEITY study tumor evolution and tumor heterogeneity” Neal G. Copeland University of Texas MD Anderson Cancer Center, US 14:45 - 15:00 “Cell-of-origin of prostate cancer and clinical heterogeneity” Esther Baena CRUK Manchester Institute, UK 15:00 - 15:15 “A clonal expression biomarker improves prognostic accuracy in lung cancer” Dhruvas Biswas UCL Cancer Institute, London, UK 15:15 - 15:45 “Transposon mutagenesis identifies genes and evolutionary forces driving gastrointestinal tract tumor progression” Nancy Jenkins University of Texas MD Anderson Cancer Center, US 15:45 - 16:15 Coffee break (social room) 16:15 - 16:30 “MGMT genomic rearrangements contribute to chemotherapy resistance and tumour relapse in gliomas” Massimo Squatrito Spanish National Cancer Research Centre, Madrid, Spain CNIO - LA CAIXA FRONTIERS MEETINGS | 2019 13 PROGRAMME 23rd September 2019 - Monday 16:30 - 17:00 “Cancer drivers and dependencies” Scott W. Lowe Memorial Sloan Kettering Cancer Center, New York, US 17:00 - 18:00 Poster Session & Wine and cheese (social room) 24th September 2019 - Tuesday 09:00 - 11:15 S#3 Chairperson: Scott Lowe 09:00 - 09:30 “The statistical ensemble approach to adaptive immunity” Curtis Callan Physics Department, Princeton University, Princeton, US 09:30 - 10:00 “Mutant p53 activities in somatic models of osteosarcoma and breast cancer” Guillermina Lozano University of Texas Anderson Cancer Center, US 10:00 - 10:15 “Predicting tumor evolution using cancer progression models” Ramón Díaz Uriarte Autonomous University of Madrid, Spain HETEROGENEITY AND EVOLUTION IN CANCER HETEROGENEITY 10:15 - 10:45 “Quantifying tumor evolution across time and space Benjamin J. Raphael Lewis-Sigler Institute for Integrative Genomics, Princeton, US 10:45 - 11:15 “Heterogeneous Immune Determinants of Tumor Evolution” Benjamin D. Greenbaum Icahn School of Medicine at Mount Sinai, New York, US 11:15 - 11:45 Coffee break (social room) 14 CNIO - LA CAIXA FRONTIERS MEETINGS | 2019 PROGRAMME
Load more

Recommended publications
  • UKI NETS 11Th National Conference 25 November 2013 the Royal College of Physicians London, UK
    UKI NETS 11th National Conference 25 November 2013 The Royal College of Physicians London, UK Abstract Marking Panel Alan Anthoney (Leeds, UK) Simon Aylwin (London, UK) Dr Tu Vinh Luong (London, UK) Prakesh Manoharan (Manchester, UK) Nick Reed (Glasgow, UK) UKI NETS would like to thank their sponsors for their kind generosity: Educational Sponsors: Meeting Sponsor: UKI NETS Euro House 22 Apex Court Tel: +44-(0)1454 642277 Woodlands Fax: +44-(0)1454 642222 Bradley Stoke Email: [email protected] Bristol, BS32 4JT, UK Website: www.ukinets.org 2 Contents Pages Programme 4 – 6 Speaker Biographies 7 - 10 Abstracts 12 – 67 3 Programme CPD UKI NETS 11TH NATIONAL CONFERENCE has been approved by the Federation of the Royal Colleges of Physicians of the United Kingdom for 6 category 1 (external) CPD credits. 08:30 Registration, Coffee and Poster viewing 09:25 Welcome and opening remarks Nick Reed (Glasgow, UK) 09:30 – 11:00 Session 1 – Pancreatic NETS –who when and how to intervene? Chair: Graeme Poston 09:30 Imaging assessment of the incidental pancreatic mass Dylan Lewis (London, UK) 09:50 Management of pancreatic primary in presence of metastatic disease Massimo Falconi (Torrette-Ancona, Italy) 10:10 Localisation of insulinoma Karim Meeran (London, UK) 10:30 Surgical approach to the pancreas and parathyroid in patients with MEN1/VHL Barney Harrison (Sheffield, UK) 10:50 Open Floor Q&A 11:00 Coffee, poster viewing and exhibition 11:30 - 12:15 Session 2a – Management dilemmas - Debate – Chemotherapy is first line treatment for pancreatic metastatic
    [Show full text]
  • Trustees' Annual Report and Financial Statements 31 March 2016
    THE FRANCIS CRICK INSTITUTE LIMITED A COMPANY LIMITED BY SHARES TRUSTEES’ ANNUAL REPORT AND FINANCIAL STATEMENTS 31 MARCH 2016 Charity registration number: 1140062 Company registration number: 6885462 The Francis Crick Institute Accounts 2016 CONTENTS INSIDE THIS REPORT Trustees’ report (incorporating the Strategic report and Directors’ report) 1 Independent auditor’s report 12 Consolidated statement of financial activities 13 Balance sheets 14 Cash flow statements 15 Notes to the financial statements 16 1 TRUSTEES’ REPORT (INCORPORATING THE STRATEGIC REPORT AND DIRECTORS’ REPORT) The trustees present their annual directors’ report together with the consolidated financial statements for the charity and its subsidiary (together, ‘the Group’) for the year ended 31 March 2016, which are prepared to meet the requirements for a directors’ report and financial statements for Companies Act purposes. The financial statements comply with the Charities Act 2011, the Companies Act 2006, and the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK (FRS102) effective 1 January 2015 (Charity SORP). The trustees’ report includes the additional content required of larger charities. REFERENCE AND ADMINISTRATIVE DETAILS The Francis Crick Institute Limited (‘the charity’, ‘the Institute’ or ‘the Crick) is registered with the Charity Commission, charity number 1140062. The charity has operated and continues to operate under the name of the Francis Crick
    [Show full text]
  • Paterson Institute for Cancer Research Scientific Report 2008 Contents
    paterson institute for cancer research scientific report 2008 cover images: Main image supplied by Karim Labib and Alberto sanchez-Diaz (cell cycle Group). Budding yeast cells lacking the inn1 protein are unable to complete cytokinesis. these cells express a fusion of a green fluorescent protein to a marker of the plasma membrane, and have red fluorescent proteins attached to components of the spindle poles and actomyosin ring (sanchez-Diaz et al., nature cell Biology 2008; 10: 395). Additional images: front cover image supplied by Helen rushton, simon Woodcock and Angeliki Malliri (cell signalling Group). the image is of a mitotic spindle in fixed MDcK (Madin-Darby canine kidney) epithelial cells, which have been stained with an anti-beta tubulin antibody (green), DApi (blue) and an anti-centromere antibody (crest, red) which recognises the kinetochores of the chromosomes. the image was taken on the spinning disk confocal microscope using a 150 x lens. rear cover image supplied by Andrei ivanov and tim illidge (targeted therapy Group). Visualisation of tubulin (green) and quadripolar mitosis (DnA stained with DApi), Burkitt’s lymphoma namalwa cell after 10 Gy irradiation. issn 1740-4525 copyright 2008 © cancer research UK Paterson Institute for Cancer Research Scientific Report 2008 Contents 4 Director’s Introduction Researchers’ pages – Paterson Institute for Cancer Research 8 Crispin Miller Applied Computational Biology and Bioinformatics 10 Geoff Margison Carcinogenesis 12 Karim Labib Cell Cycle 14 Iain Hagan Cell Division 16 Nic Jones
    [Show full text]
  • Teri Melese, Ph.D
    Prepared: 02/015 University of California, San Diego Curriculum Vitae Name: Teri Melese, Ph.D Current Position: UCSD Assistant Vice Chancellor, Industry Research Alliances Adjunct Associate Professor, Department of Medicine and Rady School of Management Last Position Held: Adjunct Associate Professor UCSF Department of Medicine, School of Medicine, 2005-2012 UCSF Dean’s Office: Director of Business Strategy and Development, School of Medicine UCSF Helen Diller Comprehensive Cancer Center Executive Committee: Associate Director for Strategic Alliances Address: University of California, San Diego Office of Research Affairs 9500 Gilman Drive #0910 La Jolla, CA 92093-0043 Tel: (858) 822-5247 mobile: (408) 373-3651 [email protected] Education: 1975-77 University of California, Berkeley A.B. Neurobiology/ Literature 1977-82 University of California, San Francisco Ph.D. Regents Fellow 1982-86 University of California, Los Angeles Postdoctoral Fellow Biochemistry 1986-87 University of California, Los Angeles American Cancer Sr. Research Fellow Molecular Biology Principal Positions Held: 1988-92 Columbia University, New York Assistant Professor Biological Sciences 1993-97 Columbia University, New York Associate Professor Biological Sciences 1997-99 Columbia University, New York Adjunct Associate Professor Biological Sciences 1997-01 Iconix Pharmaceuticals Mountain View Founding Member & Director Chemical Genomics 2001-2012 University of California, San Francisco Adjunct Full Professor Step II Medicine Present University of California, San Diego
    [Show full text]
  • Life Changing Science
    LIFE CHANGING SCIENCE The Francis Crick Institute Annual Review 2017/18 AN INSTITUTE FOR DISCOVERY Our commitment to excellence, our emphasis on multidisciplinary research, our focus on young and emerging talent and our novel ways of partnership working are some of the factors that set the Crick apart. Front cover Vaccinia virus infection (green) disrupts a layer of epithelial cells (red/blue). Courtesy of Michael Way, Group Leader at the Crick. INTRODUCTION 2 Who we are Our year at a glance 2 Introduction by Paul Nurse 4 The Francis Crick Institute is a biomedical Progress against our strategy 6 discovery institute dedicated to understanding the RESEARCH HIGHLIGHTS 10 Cancer-causing mutation fundamental biology underlying health and disease. suppresses immune system 11 Our work is helping to build an understanding of Predicting lung cancer’s return 12 New understanding of human why disease develops and to translate discoveries embryo development 14 Chemical attraction could improve into new ways to prevent, diagnose and treat cancer immunotherapy 16 illnesses such as cancer, heart disease, stroke, Genes linked to malaria parasites’ persistence 17 infections and neurodegenerative diseases. Architecture of our ‘second brain’ 18 Cause of infertility side-stepped in mice 19 Mechanism for spinal cord development discovered 20 A new layer of complexity in embryo development 21 Two DNAs wedded with this ring 22 Unravelling how DNA gets copied 23 Telomerase’s dark side discovered 24 REVIEW OF THE YEAR 26 New group leaders arrive 27 Joined-up thinking 30 Focusing on the molecules of life 32 CryoEM at the Crick 34 Bringing academia and industry closer together 36 The people making research happen 38 Patterns in art and science 40 Rewarding research 42 Appointments 43 Supporting new discoveries 44 Our vision What’s inside Our vision is to be a world- We bring together outstanding scientists Science feature 32 leading multidisciplinary from all disciplines and carry out research Sophisticated microscopy is being biomedical research institute.
    [Show full text]
  • Molecular Chaperones in Cancer
    CNIO - SPANISH”LA CAIXA”NATIONAL CANCER FOUNDATION RESEARCH CENTRE FRONTIERS MEETINGS 2017 Madrid 2nd- 4th May 2017 MOLECULAR CHAPERONES IN CANCER IN MEMORY OF SUSAN LINDQUIST Organisers Nabil Djouder Spanish National Cancer Research Centre (CNIO), Madrid, Spain Wilhelm Krek Institute for Molecular Health Sciences Zurich, Switzerland Paul Workman The Institute of Cancer Research London, UK Xiaohong Helena Yang Cancer Cell Cambridge, US EXCELENCIA MINISTERIO DE ECONOMÍA, INDUSTRIA SEVERO Y COMPETITIVIDAD OCHOA CNIO - SPANISH”LA CAIXA”NATIONAL CANCER FOUNDATION RESEARCH CENTRE FRONTIERS MEETINGS 2017 Madrid 2nd- 4th May 2017 MOLECULAR CHAPERONES IN CANCER CNIO - SPANISH”LA CAIXA”NATIONAL CANCER FOUNDATION RESEARCH CENTRE FRONTIERS MEETINGS 2017 Madrid 2nd- 4th May 2017 MOLECULAR CHAPERONES IN CANCER Summary 07 PROGRAMME 19 KEYNOTE LECTURE 23 SESSIONS 23 S #1 PROTEIN QUALITY CONTROL 31 S #2 FOLDING, MISFOLDING AND AGGREGATION 41 S #3 STRESS MECHANISMS IN CANCER 49 S #4 CHAPERONES IN CANCER 59 S #5 TARGETING CHAPERONES: CHAPERONOTHERAPY 67 CLOSING LECTURE 69 ORGANISERS AND SPEAKERS’ BIOGRAPHIES 99 POSTER SESSIONS 119 Previous CNIO Frontiers Meetings and CNIO Cancer Conferences 05 CNIO - SPANISH”LA CAIXA”NATIONAL CANCER FOUNDATION RESEARCH CENTRE FRONTIERS MEETINGS 2017 Madrid 2nd- 4th May 2017 MOLECULAR CHAPERONES IN CANCER PROGRAMME 07 PROGRAMME Madrid 2nd- 4th May 2017 MOLECULAR CHAPERONES IN CANCER Venue: Spanish National Cancer Research Centre – CNIO Auditorium, Madrid, Spain Chairpersons and organizing committee: Nabil Djouder, Spanish National Cancer Research Centre, Madrid, Spain Wilhelm Krek, Institute for Molecular Health Sciences, ETH, Zurich, Switzerland Paul Workman, The Institute of Cancer Research, London, UK Xiaohong Helena Yang, Cancer Cell, Cambridge, USA Rationale: Molecular chaperones play key roles in the folding, stability and activity of proteins in normal cell homeostasis and disease pa- thology, including cancer.
    [Show full text]
  • New Frontiers
    PROGRAM & BOOK OF ABSTRACTS JUNE 13-16, 2009 • PORTLAND, OREGON New Frontiers Children’s Tumor FoundaTION 95 PINE STREET, 16TH FLOOR, NEW YORK, NY 10005 | WWW.CTF.ORG | 212.344.6633 Dear NF Conference Attendees: On behalf of the Children’s Tumor Foundation, welcome to the 2009 NF Conference: New Frontiers. The theme references the meeting content and also Portland itself, historically a gateway port of the Pacific North West. The urban setting offers a ‘new frontier’ in comparison to the mountain and beach locales of past NF Conferences, but one which we feel you will enjoy. Portland is an easy-going city offering history, beauty and relaxation – features encapsulated in our host hotel The Nines, itself a part of the tapestry of Portland history, renovated from the former landmark Meier & Frank department store. The last year has seen major NF research advances. The dovetailing of discovery, translation and the clinic can be seen throughout the meeting. We are firmly in the age of NF clinical trials and proud that the Children’s Tumor Foundation is part of this advance: in 2009 we funded our first two pilot Clinical Trial Awards. We continue to build a pipeline of candidate NF drug therapies through the Foundation’s multi-center NF Preclinical Consortium and the seed grant Drug Discovery Initiative (DDI) program. Through these translational initiatives we are cultivating NF collaborations with the biotechnology and pharmaceutical sector, a critical factor in moving NF research forward to the clinic. At the same time, basic research advances continue, such as in the unraveling of schwannomatosis.
    [Show full text]
  • Charles Swanton MRCP Bsc Phd Fibiol
    Charles Swanton MRCP BSc PhD Biography Charles completed the MDPhD programme at University College London in 1999 having gained his PhD from the laboratory of Nic Jones at the Imperial Cancer Research Fund Laboratories establishing the subversion of cell cycle control by the Kaposi’s Sarcoma Herpesvirus encoded K-Cyclin (Swanton et al. Nature 1997) and was awarded the national Pontecorvo Imperial Cancer Research Fund PhD thesis award (Mann et al., 1999; Swanton et al., 1999; Swanton et al., 1997). Charles continued his interest in cell cycle disruption in cancer and its therapeutic applications (Swanton, Lancet Oncology 2004) and was made a Member of the Royal College of Physicians in 2003 and subsequently undertook his medical oncology training at the Royal Marsden Hospital. He was awarded a Cancer Research UK (CR-UK) clinician scientist fellowship in 2004 which allowed him to conduct his post-doctoral research training at the CR-UK London Research Institute with Prof Julian Downward, establishing multi-drug sensitivity mechanisms through RNA interference screening approaches, associated with paclitaxel and other common chemotherapy agents used in oncological practice (Swanton et al., 2007a; Swanton et al., 2007b). These screening datasets resulted in the observation that molecules that mediate chromosomal stability appeared to be significantly associated with those mediating taxane sensitivity and led to the first phase II clinical trial in colorectal cancer to attempt to define prospectively whether tumour chromosomal instability status alters response to a taxane-like drug. In 2008, Charles was awarded an MRC and a CR-UK senior clinical research fellowship and appointed MRC/CR-UK Group leader of the Translational Cancer Therapeutics Laboratory at the CRUK London Research Institute and Fellow of the Society of Biologists (FSB).
    [Show full text]
  • Cancer Research UK Gurdon Institute Prospectus 2020/2021 25 YEARS
    The Wellcome/ Cancer Research UK Gurdon Institute Prospectus 2020/2021 25 YEARS The Wellcome/ Cancer Research UK Gurdon Institute Studying Prospectus 2020/2021 E development to C U G E N D E R E R understand disease C HA R T The Gurdon Institute 3 Contents Welcome Welcome to our new Prospectus, where we highlight our Watermark, the first such award in the University. Special activities for - unusually - two years: 2019 and 2020. The thanks for this achievement go to Hélène Doerflinger, COVID-19 pandemic has made it an extraordinary time Phil Zegerman and Emma Rawlins. Director’s welcome 3 Emma Rawlins 38 for everyone. I want to express my pride and gratitude for the exceptional efforts of Institute members, After incubating Steve Jackson's company Adrestia in About the Institute 4 Daniel St Johnston 40 who have kept our building safe and our research the Institute for two years, we wished them well as they progressing; this applies especially to our core team, moved to the Babraham Research Campus. We also sent COVID stories 6 Ben Simons 42 whose dedication has been key to our best wishes to Meri Huch and our continued progress. As you will Rick Livesey and their labs, as they Highlights in 2019/2020 8 Azim Surani 44 see, there is much to be excited embarked on their new positions in about in our research and activities. Dresden and London, respectively. Focus on research Iva Tchasovnikarova 46 It was terrific to see Gurdon I'm delighted that Emma Rawlins Group leaders Fengzhu Xiong 48 members receive recognition for was promoted to Senior Group their achievements.
    [Show full text]
  • November 2020 | YOUR IMPACT | LORD LEONARD and LADY ESTELLE WOLFSON FOUNDATION NOVEMBER 2020 YOUR IMPACT
    1 | November 2020 | YoUr ImPACT | LorD LEONArD AND LADY eSTeLLe WoLFSoN FoUNDATIoN NOVEMBER 2020 YOUR IMPACT PREPARED FOR THE LORD LEONARD AND LADY ESTELLE WOLFSON FOUNDATION Together we will beat cancer Sir Paul Nurse THANK YOU FOR YOUR SUPPORT Since opening its doors in November 2016, the Crick is establishing its reputation as one of the leading biomedical discovery research institutes in the world. So far, Crick scientists have produced more than 2,500 research publications, which are advancing our fundamental understanding of human health and disease. We are delighted to have your ongoing commitment to support Sir Paul Nurse and his team’s work to understand the intricate processes controlling the cell cycle. Here, we are pleased to present you with an update from Paul and his team in the Cell Cycle Laboratory, as well as a round-up of some of the pioneering advances that the Crick’s researchers have made over the past year. view from the 5th floor of the Francis Crick Institute HIGHLIGHTS AND ACHIEVEMENTS 2,500+ research papers have been published since the Crick opened, sharing new discoveries and AWARDS IN 2020 ideas that could transform the way we approach disease 12 early career group leaders Professor Sir Peter ratcliffe and Professor were appointed this past year, selected Charles Swanton were elected to join the from a pool of 371 applications submitted American Association for Cancer research from across the globe Academy in recognition of their significant The Crick is 5th in the world contributions to innovation and progress
    [Show full text]
  • LONG-TERM MEMBERS 25+ Years of Membership
    LONG-TERM MEMBERS 25+ Years of Membership Stuart A. Aaronson, MD Stephen P. Ackland, MBBS Carol Aghajanian, MD Steven A. Akman, MD Icahn School of Medicine at Mount Sinai University of Newcastle Memorial Sloan Kettering Cancer Center Roper St. Francis Healthcare United States Australia United States United States Active Member Active Member Active Member Active Member 38 Years of Membership 33 Years of Membership 27 Years of Membership 35 Years of Membership Cory Abate-Shen, PhD Edward M. Acton, PhD Irina U. Agoulnik, PhD Emmanuel T. Akporiaye, PhD Columbia University Irving Medical United States Florida International University Verana Therapeutics Center Emeritus Member United States United States United States 42 Years of Membership Active Member Emeritus Member Active Member 25 Years of Membership 31 Years of Membership 26 Years of Membership David J. Adams, PhD Duke University Medical Center Imran Ahmad, PhD Ala-Eddin Al Moustafa, PhD James L. Abbruzzese, MD United States Northwestern Medicine McGill University Duke University Emeritus Member United States Canada United States 32 Years of Membership Active Member Active Member Active Member 25 Years of Membership 26 Years of Membership 32 Years of Membership Gregory P. Adams, PhD Elucida Oncology Nihal Ahmad, PhD Abdul Al Saadi, PhD Ehtesham A. Abdi, MBBS United States Univ. of Wisconsin Madison Sch. of Med. William Beaumont Hospital The Tweed Hospital Active Member & Public Health United States Australia 29 Years of Membership United States Emeritus Member Emeritus Member Active Member 52 Years of Membership 33 Years of Membership Lucile L. Adams-Campbell, PhD 25 Years of Membership Georgetown Lombardi Comprehensive Suresh K.
    [Show full text]
  • Donation: the Lifeblood of the NHS
    News from the Medical Research Council Autumn 2018 network Leading science for better health Bl d donation: the lifeblood of the NHS Opinion: How secure data sharing can help us treat dementia Network can also be downloaded as a PDF at: mrc.ukri.org/network CONTENTS News COMMENT FROM Happy birthday to the NHS! 4 Health data: first UK snapshot review 5 Fiona Watt EXECUTIVE CHAIR People As the UK Research and Innovation Royal recognition for Nobel Prize-winner 9 Champion for Talent and Skills, I'm passionate about supporting researchers at the most pivotal points of their careers. It seems clear that we should be investing in Funding the best people, regardless of career stage and geography. £900m for future leaders 15 To help build expertise and opportunities for future careers, we're adding more activities to the list of those eligible to researchers employed on MRC grants, to cover activities that do not directly relate to their Latest discoveries specific research project. Potential therapy identified for common Supporting the career development of research staff is cause of dementia 16 equally important as supporting our researchers. That's why we've introduced a new 'research co-investigator' status for Eye drops with turmeric extract could research staff on MRC grants, to provide recognition for treat common eye disease 17 their intellectual research contributions and to help career development (see page 3). Sharing data and recognising individual research contributions are vital, especially for early-career Features researchers. I'm pleased to see the Dementias Platform UK leading the way with their data portal – a secure platform Blood donation: the lifeblood of the NHS 6 for sharing and analysing dementia research data.
    [Show full text]